The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Yselty linzagolix choline Additional monitoring | Theramex Ireland Limited | Leiomyoma | 🇪🇺 EU 2022-06-14 | Order → |
| Lunsumio mosunetuzumab OrphanConditionalAdditional monitoring | Roche Registration GmbH | Lymphoma, Follicular | 🇪🇺 EU 2022-06-03 | Order → |
| Zolsketil pegylated liposomal doxorubicin | Accord Healthcare S.L.U. | Ovarian Neoplasms; Sarcoma, Kaposi; Multiple Myeloma | 🇪🇺 EU 2022-05-31 | Order → |
| Carvykti ciltacabtagene autoleucel OrphanPRIMEATMP | Janssen-Cilag International NV | Multiple Myeloma | 🇪🇺 EU 2022-05-25 | Order → |
| Camcevi leuprorelin | Accord Healthcare S.L.U. | Prostatic Neoplasms | 🇪🇺 EU 2022-05-24 | Order → |
| Amifampridine SERB amifampridine Generic | SERB SA | Myasthenia Gravis | 🇪🇺 EU 2022-05-19 | Order → |
| Dimethyl fumarate Mylan dimethyl fumarate Generic | Mylan Ireland Limited | Multiple Sclerosis, Relapsing-Remitting | 🇪🇺 EU 2022-05-13 | Order → |
| Dimethyl fumarate Neuraxpharm dimethyl fumarate Generic | Laboratorios Lesvi S.L. | Multiple Sclerosis, Relapsing-Remitting | 🇪🇺 EU 2022-05-13 | Order → |
| Dimethyl fumarate Polpharma dimethyl fumarate Generic | Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A. | Multiple Sclerosis, Relapsing-Remitting | 🇪🇺 EU 2022-05-13 | Order → |
| Amversio betaine anhydrous Generic | SERB SA | Homocystinuria | 🇪🇺 EU 2022-05-05 | Order → |
| Orgovyx relugolix Additional monitoring | Accord Healthcare S.L.U. | Prostatic Neoplasms | 🇪🇺 EU 2022-04-29 | Order → |
| Quviviq daridorexant Additional monitoring | Idorsia Pharmaceuticals Deutschland GmbH | Sleep Initiation and Maintenance Disorders | 🇪🇺 EU 2022-04-29 | Order → |
| Inpremzia insulin human (rDNA) BiosimilarAdditional monitoring | Baxter Holding B.V. | Diabetes Mellitus | 🇪🇺 EU 2022-04-25 | Order → |
| Kapruvia difelikefalin Additional monitoring | Vifor Fresenius Medical Care Renal Pharma France | Pruritus | 🇪🇺 EU 2022-04-25 | Order → |
| PreHevbri hepatitis B surface antigen Additional monitoring | VBI Vaccines B.V. | Hepatitis B | 🇪🇺 EU 2022-04-25 | Order → |
| Sitagliptin Accord sitagliptin Generic | Accord Healthcare S.L.U. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2022-04-25 | Order → |
| Truvelog Mix 30 insulin aspart BiosimilarAdditional monitoring | Sanofi Winthrop Industrie | Diabetes Mellitus | 🇪🇺 EU 2022-04-25 | Order → |
| Uplizna inebilizumab Additional monitoring | Amgen Europe B.V. | Neuromyelitis Optica | 🇪🇺 EU 2022-04-25 | Order → |
| Vydura rimegepant Additional monitoring | Pfizer Europe MA EEIG | Migraine Disorders | 🇪🇺 EU 2022-04-25 | Order → |
| Padcev enfortumab vedotin Additional monitoring | Astellas Pharma Europe B.V. | Carcinoma, Transitional Cell; Urologic Neoplasms | 🇪🇺 EU 2022-04-13 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.